Skip to content
Heart icon (animated) heart icon (static)
Our Stories
Explore more Johnson & Johnson sites:
Switzerland
Heritage

70 Years of Johnson & Johnson in India 70 Years of Johnson & Johnson in India

Johnson & Johnson spread its root into India 70 years ago. Since then, the company has brought many innovative ideas, products and services to improve the health and well-being of people in India. The company today employs more than 3,500 people and is organized into three business segments: Consumer Healthcare, Medical Devices and Pharmaceuticals.

Consumer Healthcare
The consumer division of Johnson & Johnson India has a portfolio of iconic brands that are #1 or #2 in their categories. Our products, across baby care, feminine hygiene, face care, OTC, oral care and wound care, feature brands such as Johnson's Baby®, Stayfree®, Clean & Clear®, Benadryl®, Listerine®, BAND-AID® and ORSL™ that are trusted by consumers and healthcare professionals in India and around the world. By anticipating needs and creating solutions and experiences, we help people live healthy, vibrant lives.

Medical Devices
Having made significant contributions to surgery for more than 60 years in India, the medical division of Johnson & Johnson India is the largest medical devices company in India with products dedicated to addressing unmet needs in the fields of orthopaedics, cardiovascular disease, coronary artery disease, peripheral vascular and obstructive disease, neurovascular disease, arrhythmias, diabetes care, bariatric and metabolic surgery, cancer surgery, vision care, general surgery, urologic surgery, hernia surgery and infection prevention. We touch the lives of around 40 million patients every year.

Pharmaceuticals
Janssen India, the pharmaceutical division of Johnson & Johnson India, is dedicated to addressing and solving some of the most important unmet medical needs of our time in India, in oncology, immunology, neuroscience and analgesia, dermatology, infectious diseases and metabolic diseases. At Johnson & Johnson India, we continue to be driven by a vision of caring for the people by anticipating their needs, creating solutions and experiences that help them and those that they care for living live healthy, vibrant lives.

  • 1947

    Johnson & Johnson Spreads Its Roots to India

    In 1947, Johnson & Johnson expands into India, marketing Johnson’s® Baby Powder. Today, Johnson’s® remains a trusted brand by mothers and doctors.

    Read More
  • 1957

    Johnson & Johnson Is Incorporated in India

    In September 1957, Johnson & Johnson incorporated a separate legal entity in India with 12 employees. Today, the company employs 6,040 people across three business segments: consumer products, medical devices and pharmaceuticals.

    Read More
  • 1959

    The First Manufacturing Facility for Consumer Products Is Established in Mumbai

    Production began in 1959 at the Johnson & Johnson India plant in Mulund, Mumbai, for Johnson’s® Baby Powder, BAND-AID® and specialized products.

    Read More
  • 1962

    The First Medical Devices (Sutures) Manufacturing Facility Is Established

    In 1962, the first Ethicon suture manufacturing facility was set up in Mumbai for catgut sutures. Suture manufacturing was expanded with full-fledged state-of-the-art plants in Aurangabad (1991) and Baddi (2007), respectively.

    Read More
  • 1968

    Johnson & Johnson Begins Manufacturing Sanitary Napkins

    In 1968, the company introduces the Stayfree® brand to India. Prior to this, women had to rely on homemade methods that were often ineffective

    Read More
  • 1975

    A Pharmaceutical and Ethical Products Manufacturing Facility Is Established

    Ethnor Ltd (merged with Johnson & Johnson in 1994) set up a plant for manufacturing pharmaceutical and ethical products of Ortho McNeil Laboratories and Cilag Chemie (members of the Johnson & Johnson family of companies).

    Read More
  • 1975

    Vicryl® Sutures Enter the Market

    The Vicryl® Suture, a synthetic absorbable suture that can be naturally absorbed into the skin, was launched in India. In 2008, a triclosan-coated version of the Vicryl® Plus Antibacterial Suture was introduced. Today, in the field of synthetic absorbable sutures, the company also offers PDS® and Monocryl® sutures.

    Read More
  • 1989

    The Ethicon Plant Receives the President’s Safety Award

    The Ethicon catgut manufacturing facility was awarded the prestigious President's Safety Award in 1989, a recognition of the company’s high manufacturing safety and quality standards.

    Read More
  • 1993

    The First Professional Education Institute for Healthcare Professionals Is Established

    To help improve access to quality healthcare and accelerate the building of a skilled India, Johnson & Johnson India took a pioneering step in 1993 by establishing its first professional education institute–the Ethicon Institute of Surgical Education (EISE) in Mumbai. Since then, the company has trained more than 250,000 healthcare professionals through its owned institutes and via partnerships with government and educational institutions.

    Read More
  • 1998

    DePuy Joins the Johnson & Johnson Family of Companies

    In 1998, Johnson & Johnson acquired DePuy followed by Synthes in 2012 to tackle some of the toughest problems in the orthopaedics industry. Today, their joint reconstruction, sports medicine and facial fracture repair technologies can be found in hospitals, clinics, and sports arenas across the world.

    Read More
  • 1999

    An Analytical and Pharmaceutical Development R&D Center Opens

    A commercial drug stability testing center was set up in Mulund, Mumbai, in 1999. Today, it is a full-fledged Analytical Centre of Excellence and plays a critical role in the development of new medicines for patients around the world, delivering cutting-edge development through open innovation that connects experts, researchers and partner organizations and firms. Johnson & Johnson India is one of the few multinational pharmaceutical companies with an analytical development center in the country.

    Read More
  • 2009

    The Company Begins Partnering With the Indian Academy of Pediatrics to Support Child Survival

    Johnson & Johnson India’s Neonatal Resuscitation Program was founded in 2009 and is the largest child survival project to be implemented in India. Over seven years, Johnson & Johnson India, along with the Indian Academy of Pediatrics, has trained more than 180,000 healthcare professionals and infant caregivers on resuscitation skills to reduce infant mortality in India.

    Read More
  • 2013

    Construction Begins on a New Manufacturing Facility for Consumer Products

    The foundation laid stone for Johnson & Johnson India’s largest consumer products greenfield facility in Telangana to manufacture personal hygiene and skincare products.

    Read More
  • 2015

    The Company Launches a New Class of Type 2 Diabetes Medicine in India

    In 2015, Janssen India, the pharmaceutical division of Johnson & Johnson India, introduced canagliflozin, a new class of medication called sodium glucose co-transporter 2 (SGLT2) inhibitors, for the treatment of type 2 diabetes.

    Read More
  • 2015

    The Company Partners With NIPER for a Medical Device Postgraduate Program

    Johnson & Johnson India entered a unique public-private partnership with the National Institute of Pharmaceutical Education and Research (NIPER) in Ahmedabad for a postgraduate training program for future medical devices industry regulators.

    Read More
  • 2016

    Global Clinical Operations Are Established in India

    Johnson & Johnson India establishes global clinical operations in India helping patients access and participate in global clinical trials for the company’s innovative therapies.

    Read More
  • 2016

    The Company Establishes an Innovative Partnership With the Government of India on MDR-TB

    In 2016, Janssen India donated 600 courses of bedaquiline to the Revised National Tuberculosis Control Program (RNTCP) of India for use as part of a conditional access program for multidrug-resistant tuberculosis (MDR-TB). Discovered by Janssen researchers, bedaquiline is a therapy with a novel mechanism of action against TB, and addresses a significant unmet need for patients with MDR-TB.

    Since then, the program is due to be expanded, with an additional 10,000 courses of treatment to be received by RNTCP through the Johnson & Johnson USAID donation program.

    Read More
  • 2017

    The Company Supports the Humana People to People Project, Designed to Save and Improve the Lives of Women and Children

    Johnson & Johnson began supporting the “Raising Healthy & Educated Community” project, which aims to improve the quality of life, basic and preventive healthcare and the quality of education for six villages in the Mahbubnagar district of Telangana, with its main focus on women and children. This project has successfully organized static clinic and health camps to reach out to approximately 15,000 direct beneficiaries. It also focuses on strengthening preschool education for 3- to 6-year-old children, thereby improving health as well as the quality of education in the community.

    Read More
  • 2018

    Johnson & Johnson India Joins Forces with the Government of Maharashtra to Boost Public Health in the State

    Johnson & Johnson India announced a strategic partnership with the Government of Maharashtra to implement focused disease interventions that have the potential to significantly improve the health of people and strengthen health are in the state.

    Through this collaboration, the Government of Maharashtra and Johnson & Johnson India will work together to address pressing public health issues such as tuberculosis (TB), maternal and child health, infection prevention, diabetes, obesity and menstrual hygiene, and will support healthcare professionals and nurses in the state to further develop their skills in these areas.

    Read More
Back to top